Analysts expect Intec Pharma Ltd. (NASDAQ:NTEC) to report ($0.28) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Intec Pharma’s earnings, with estimates ranging from ($0.29) to ($0.27). The company is scheduled to report its next quarterly earnings report on Friday, June 8th.
According to Zacks, analysts expect that Intec Pharma will report full year earnings of ($1.15) per share for the current financial year, with EPS estimates ranging from ($1.22) to ($1.06). For the next fiscal year, analysts forecast that the business will post earnings of ($0.91) per share, with EPS estimates ranging from ($1.25) to ($0.54). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Intec Pharma.
Intec Pharma (NASDAQ:NTEC) last issued its earnings results on Friday, March 9th. The biotechnology company reported ($0.39) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.19).
Several research analysts have recently commented on NTEC shares. Oppenheimer set a $15.00 price target on Intec Pharma and gave the stock a “buy” rating in a research report on Monday, December 18th. Zacks Investment Research lowered Intec Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, December 19th. HC Wainwright started coverage on Intec Pharma in a research report on Monday, February 26th. They issued a “buy” rating for the company. Finally, Ladenburg Thalmann started coverage on Intec Pharma in a research report on Wednesday, February 28th. They issued a “buy” rating for the company. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $12.67.
NTEC opened at $6.30 on Wednesday. Intec Pharma has a 12 month low of $4.80 and a 12 month high of $9.80.
A number of hedge funds have recently made changes to their positions in NTEC. Deutsche Bank AG grew its stake in Intec Pharma by 59.2% during the 4th quarter. Deutsche Bank AG now owns 115,217 shares of the biotechnology company’s stock valued at $593,000 after purchasing an additional 42,867 shares during the last quarter. Caxton Corp purchased a new stake in Intec Pharma during the 3rd quarter valued at about $681,000. Renaissance Technologies LLC grew its stake in Intec Pharma by 66.0% during the 4th quarter. Renaissance Technologies LLC now owns 133,500 shares of the biotechnology company’s stock valued at $688,000 after purchasing an additional 53,100 shares during the last quarter. Pura Vida Investments LLC purchased a new stake in Intec Pharma during the 3rd quarter valued at about $895,000. Finally, Millennium Management LLC purchased a new stake in Intec Pharma during the 4th quarter valued at about $1,392,000. Hedge funds and other institutional investors own 41.39% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Anticipate Intec Pharma Ltd. (NTEC) Will Post Earnings of -$0.28 Per Share” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/09/zacks-brokerages-anticipate-intec-pharma-ltd-ntec-will-post-earnings-of-0-28-per-share.html.
Intec Pharma Company Profile
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Get a free copy of the Zacks research report on Intec Pharma (NTEC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.